Syngene International has expanded its ongoing collaboration with Bristol-Myers Squibb. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026. The expansion will enable the two companies to undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities.
As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 square feet of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively in support of Bristol-Myers Squibb.
Syngene International is India’s largest Contract Research Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides.
